Neuberger Berman Group
PTGX icon

Neuberger Berman Group’s Protagonist Therapeutics PTGX Stock Holding History

Neuberger Berman Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9M Buy
141,441
+42,968
+44% +$3.8M 0.01% 729
2025
Q4 		$8.6M Sell
98,473
-24,904
-20% -$2.04M 0.01% 839
2025
Q3 		$8.2M Buy
123,377
+29,795
+32% +$1.69M 0.01% 851
2025
Q2 		$5.17M Buy
+93,582
New +$4.49M ﹤0.01% 959

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Neuberger Berman Group's PTGX Position: Q1 2026 in Review

Neuberger Berman Group increased its Protagonist Therapeutics (PTGX) stake by 44% in Q1 2026, buying an estimated $3.8M and bringing the position to 141,441 shares worth $14.9M. The position accounts for 0.01% of the portfolio, ranked #729.

Neuberger Berman Group first reported a position in PTGX in Q2 2025 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Neuberger Berman Group held 141,441 shares of Protagonist Therapeutics worth $14.9M as of Q1 2026.
  • Neuberger Berman Group bought 42,968 Protagonist Therapeutics shares in Q1 2026, an estimated $3.8M.
  • Protagonist Therapeutics made up 0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #729 holding.
  • Neuberger Berman Group first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.